APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway

Overview of attention for article published in BMC Neurology, April 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news: 1 news outlet
blogs: 2 blogs

q&a: 1 Q&A thread

Citations

dimensions_citation: 209 Dimensions

Readers on

mendeley: 191 Mendeley
citeulike: 1 CiteULike

Summary News Blogs Q&A Dimensions citations

So far, Altmetric has seen 1 Q&A post.

Will CRISPR/CAS9 be used to replace EPOA4 with EPOA3/2 in humans in vivo in the near future?

Posted by Peter Nordin, at medicalsciences.stackexchange.com, 02 Jun 2018

How likely is it that CRISPR/CAS9 will be available as treatment to replace APOE4 with APOE3/2 in humans in vivo in the near…

This page shows the most recent Q&A posts that mention this research output.

Click here to find out how to access more activity.